Возможность и перспективы применения препарата колхицин у пациентов с COVID-19, обновление обзора


DOI: https://dx.doi.org/10.18565/pharmateca.2021.2.8-11

Ю.Ю. Киселев (1), А.В. Матвеев (2)

1) Oslo Metropolitan University, Норвегия, https://orcid.org/0000-0002-6753-8572; 2) Российская медицинская академия непрерывного профессионального образования, Москва, Россия, https://orcid.org/0000-0002-6636-3950
Существуют теоретические предпосылки к применению колхицина в лечении пациентов с COVID-19, ведутся клинические исследования. На сегодня существуют лишь ограниченные опубликованные данные, указывающие на возможную эффективность применения колхицина при COVID-19. Эти данные пока не позволяют рекомендовать его для широкой практики. При использовании колхицина важно осуществлять клинический и гематологический контроль и избегать лекарственных взаимодействий.
Ключевые слова: COVID-19, колхицин

Литература


1. URL: https://grls.rosminzdrav.ru/.


2. URL: https://www.medicines.org.uk/emc/product/6415/smpc.


3. Misawa T., Takahama M., Kozaki T., et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat Immunol. 2013;14:454–60. Doi: 10.1038/ni.2550.


4. Hemkens L.G., Ewald H., Gloy V.L., et al. Colchicine for prevention of cardiovascular events. Cochrane Database Syst Rev. 2016;1:CD011047. Doi: 10.1002/14651858.CD011047.pub2.


5. Tardif J.C., Kouz S., Waters D.D., et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497–505. Doi: 10.1056/NEJMoa1912388.


6. Leung Y.Y., Hui L.L.Y., Kraus V.B. Colchicine-update on mechanism of action and therapeutic uses. Semin Arthr Rheum. 2015;45:341–50. Doi: 10.1016/j.semarthrit.2015.06.013.


7. Milewska A., Nowak P., Owczarek K., et al. Entry of human coronavirus NL63 into the cell. J Virol. 2018;92:e01933–17. Doi: 10.1128/JVI.01933-17.


8. Gultekin N., Kucukates E. Microtubule inhibition therapy by colchicine in severe myocarditis especially caused by Epstein-Barr and cytomegalovirus co-infection during a two-year period: a novel therapeutic approach. J Pak Med Assoc. 2014;64:1420–23.


9. Piantoni S., Patroni A., Toniati P., et al. Why not to use colchicine in COVID-19? An old anti-inflammatory drug for a novel auto-inflammatory disease


10. Nasiripour S., Zamani F., Farasatinasab M. Can Colchicine as an Old Anti-Inflammatory Agent Be Effective in COVID-19?


11. URL: https://covid19evidence.net.au/.


12. URL: https://www.covid19treatmentguidelines.nih.gov/


13. URL: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/054/662/original/%D0%92%D1%80%D0%B5%D0%BC%D0%B5%D0%BD%D0%BD%D1%8B%D0%B5_%D0%9C%D0%A0_COVID-19_%28v.10%29.pdf.


14. URL: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/clinical-management-covid-19.html.


15. URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097833/pdf/idr-12-1-8543.pdf.


16. URL: http://mc.msu.ru/protokol-COVID-MNOC.pdf?fbclid=IwAR0pcfEk_LpYL8O6YKNGEbe3b_FuEpYTbiap8JTH6ZhnVjYLzTFtHBKpYNY.


17. Della-Torre E., Della-Torre F., Kusanovic Pcp M., et al. Treating COVID-19 with colchicine in community healthcare setting


18. Cumhur Cure M., Kucuk A., Cure E. Colchicine may not be effective in COVID-19 infection; it may even be harmful?


19. Gendelman O., Amital H., Bragazzi N.L., et al. Continuous hydroxychloroquine or colchicine therapy does not prevent infection with SARS-CoV-2: Insights from a large healthcare database analysis. Autoimmun Rev. 2020;19(7):102566. Doi: 10.1016/j.autrev.2020.102566.


20. URL: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/colchicine-marketed-colcrys-information.


21. URL: https://clinicaltrials.gov/ct2/results?cond=COVID&term=colchicine&cntry=&state=&city=&dist=.


22. Reyes A.Z., Hu K.A., Teperman J., et alAnti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis.


23. URL: https://www.medrxiv.org/content/10.1101/2021.01.26.21250494v1.full.pdf.


24. Lopes M.I., Bonjorno L.P., Giannini M.C., et alBeneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial. RMD Open. 2021;7:e001455. Doi: 10.1136/rmdopen-2020-001455.


25. URL: https://www.recoverytrial.net/news/colchicine-to-be-investigated-as-a-possible-treatment-for-covid-19-in-the-recovery-trial.


Бионика Медиа